Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-02T11:17:19.864Z Has data issue: false hasContentIssue false
  • English
  • Français

Nanotechnology in Global Medicine and Human Biosecurity: Private Interests, Policy Dilemmas, and the Calibration of Public Health Law

Published online by Cambridge University Press:  01 January 2021

Thomas A. Faunce
Get access Rights & Permissions [Opens in a new window]

Extract

This article explores a unique opportunity for shaping public health law and policy to reflect a greater balance between public and private goods in two areas of primary concern to human well-being: medicine and human biosecurity. This opportunity is presented both by the rapid changes likely to occur in these areas as a result of nanotechnology and the fact that multinational corporate actors have not yet had the opportunity to use their well-honed techniques of governance influence to modify public health policy and law in this area to their own narrowly focused advantage. Such a rare opportunity to rethink some fundamental assumptions about a regulatory framework for globally important health issues in advance is one reason why issues concerning nanotechnology regulation in medicine and human biosecurity should have considerable interest to health law and policy scholars.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 35 , Issue 4 , Winter 2007 , pp. 629 - 642
Copyright
Copyright © American Society of Law, Medicine and Ethics 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Faunce, T. A., Nanotechnology in Medicine and Biosecurity: Dilemmas for Bioethics, Public Health Law and International Human Rights, lecture presented at Johns Hopkins Bloomberg School of Public Health, Baltimore, Tuesday, April 17, 2007.Google Scholar
U.S. Food and Drug Administration, Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force, July 25, 2007, available at <http://www.fda.gov/nano-technology/taskforce/report2007.html> (last visited September 15, 2007).+(last+visited+September+15,+2007).>Google Scholar
United Nations Educational, Scientific and Cultural Organization, Universal Declaration on Bioethics and Human Rights, available at <http://portal.unesco.org/en/ev.php-URL_ID=31058&URL_DO=DO_TOPIC&URL_SECTION=201.html> (last visited September 14, 2007).+(last+visited+September+14,+2007).>Google Scholar
United Nations, Office for the High Commissioner of Human Rights, available at <http://www.unhchr.ch/udhr/> (last visited September 15, 2007); United Nations, Universal Declaration of Human Rights, General Assembly Resolution 217A (III), U.N. Doc. A/810 (1948) 71, adopted December 10, 1948.+(last+visited+September+15,+2007);+United+Nations,+Universal+Declaration+of+Human+Rights,+General+Assembly+Resolution+217A+(III),+U.N.+Doc.+A/810+(1948)+71,+adopted+December+10,+1948.>Google Scholar
United Nations, International Covenant on Civil and Political Rights, General Assembly Resolution 2200A (XXI), U.N. GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, adopted December 16, 1966, entered into force March 23, 1976, reprinted in International Legal Materials 6 (1967): 368.Google Scholar
United Nations, International Covenant on Economic, Cultural and Social Rights, General Assembly Resolution 2200A (XXI), U.N. Doc. A/6316 (1966), 993 U.N.T.S. 3, adopted December 16, 1966, entered into force January 3, 1976, reprinted in International Legal Materials 6 (1966): 360.Google Scholar
Rawls, A., Theory of Justice (Oxford: Oxford University Press, 1971).Google Scholar
Brower, V., “Is Nanotechnology Ready for Primetime?” Journal of the National Cancer Institute 98, no. 1 (2006): 9–11.CrossRefGoogle Scholar
U.S. Food and Drug Administration, Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force, July 25, 2007, available at <http://www.fda.gov/nano-technology/taskforce/report2007.html> (last visited September 15, 2007) [hereinafter cited as FDA]; The Royal Society, Nanoscience and Nanotechnologies: Opportunities and Uncertainties, R.S. Policy Document 19/04, Cardiff, 2004.+(last+visited+September+15,+2007)+[hereinafter+cited+as+FDA];+The+Royal+Society,+Nanoscience+and+Nanotechnologies:+Opportunities+and+Uncertainties,+R.S.+Policy+Document+19/04,+Cardiff,+2004.>Google Scholar
Sone, J. Fujita, J. Ochiai, Y., “Nanofabrication toward Sub− 10 nm and its Application to Novel Nanodevices,” Nanotechnology 10 (1999): 135–41.CrossRefGoogle Scholar
Wagner, V. Dullart, A. Bock, A.-K. Zweck, A., “The Emerging Nanomedicine Landscape,” Nature Biotechnology 24, no. 10 (2006): 1211–18.CrossRefGoogle Scholar
Ghadiri, M. R., “Antibacterial Agents Based on the Cyclic D, L Peptide Architecture,” Nature 412 (2001): 451–55.Google Scholar
Bottini, M. Bruckner, S. Nika, K. et al. , “Multi-Walled Carbon Nanotubules Induce T Lymphocyte Apoptosis,” Toxicology Letters 160 (2006): 121–26.CrossRefGoogle Scholar
Leary, S. P. Liu, C. Y. Yu, C. et al. , “Toward the Emergence of Nanoneurosurgery: Part I-Progress in Nanoscience, Nanotechnology and the Comprehension of Events in the Mesoscale Realm,” Neurosurgery 57, no. 4 (2005): 606–33.CrossRefGoogle Scholar
Kong, D. F. Goldschmidt-Clermont, P. J., “Tiny Solutions for Giant Cardiac Problems,” Trends in Cardiovascular Medicine 15, no. 6 (2005): 207–11.CrossRefGoogle Scholar
Hulstein, J. J. et al. , “A Novel Nanobody that Detects the Gain-of-Function Phenotype of von Willebrand Factor in ADAMTS13 Deficiency and von Willebrand Disease Type 2B,” Blood 106, no. 9 (2005): 3035–42.CrossRefGoogle Scholar
Prestidge, C. A., Nanoscience Facilitating the Development of Novel Pharmaceutical Delivery Systems, abstract of paper presented at the Australian Research Council Nanotechnology Network International Conference on Nanoscience and Naotechnology, Brisbane Convention Centre, July 3–7, 2006.Google Scholar
See FDA, supra note 9.Google Scholar
Ontario Health Technology Advisory Committee, Report on Nanotechnology, available at <http://www.health.gov.on.ca/english/providers/program/ohtac/tech/techlist_2006.html> (last visited September 26, 2007).+(last+visited+September+26,+2007).>Google Scholar
See supra note 9.Google Scholar
Alberts, B., “Modeling Attacks on the Food Supply,” Proceedings of the National Academy of Sciences 102, no. 28 (2005): 9737–38.CrossRefGoogle Scholar
Wein, L. M. Liu, Y., “Analyzing a Bioterror Attack on the Food Supply: The Case of Botulinum Toxin in Milk,” Proceedings of the National Academy of Sciences 102, no. 28 (2005): 9984–89.CrossRefGoogle Scholar
Nuzzo, J. B., “The Biological Threat to U.S. Water Supplies: Toward a National Water Security Policy,” Biosecurity and Bioterrorism 4, no. 2 (2006): 147–59.CrossRefGoogle Scholar
Jackson, R. J. Ramsay, A. J. Christensen, C. D. Beaton, S. Hall, D. F. Ramshaw, I. A., “Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox,” Journal of Virology 75 (2001): 1205–10.CrossRefGoogle Scholar
Taubenberger, J. K. Reid, A. H. Lourens, R. M. Wang, R. Jin, G. Fanning, T. G., “Characterization of the 1918 Influenza Virus Polymerase Genes,” Nature 437 (2005): 889–93; Tumpey, T. M. et al. , “Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus,” Science 310 (2005): 77–80.CrossRefGoogle Scholar
Hamilton, D. S. Smith, B. T., “Atlantic Storm,” EMBO Report 7 (2006): 4–9.CrossRefGoogle Scholar
Wood, S. Jones, R. Geldart, A., “Social and Economic Challenges of Nanotechnology,” Economic and Social Research Council, Swindon, U.K., 2003.CrossRefGoogle Scholar
See generally Kahneman, D., “Maps of Bounded Rationality: Psychology for Behavioral Economics,” American Economic Review 93 (2003): 1449–75; Faunce, T. A., Who Owns Our Health? Medical Professionalism, Law and Leadership Beyond the Age of the Market State (Sydney: UNSW Press/Johns Hopkins University Press, 2007).Google Scholar
Pretty's Case [2002] 1 FLR 268, Case of Pretty v. U.K. (application no. 2346/02).Google Scholar
Minister of Health v. Treatment Action Campaign (2002) Case CCT 8/02.Google Scholar
Institute of Occupational Medicine for the Health and Safety Executive, Nanoparticles: An Occupational Hygiene Review, 2004, available at <http://www.hse.gov.uk> (last visited September 15, 2007).+(last+visited+September+15,+2007).>Google Scholar
Department of Employment and Workplace Relations (DEWR), Australian Government, Submission to Senate Inquiry into Workplace Exposure to Toxic Dusts and Nanoparticles, Canberra, August 2005.Google Scholar
See supra note 9.Google Scholar
Id.Google Scholar
Flinders Consulting Pty Ltd., A Review of the Potential Occupational Health and Safety Implications of Nanotechnology, Australian Safety and Compensation Council, 2006, available at <http://www.ascc.gov.au/ascc/AboutUs/Publications/ResearchReports/AReviewofthePotentialOccupation-alHealthandSafetyImplicationsofNanotechnology.htm> (last visited September 14, 2007).+(last+visited+September+14,+2007).>Google Scholar
Faunce, T. A., “Nanotherapeutics: New Challenges for Safety and Cost-Effectiveness Regulation in Australia,” Medical Journal of Australia 186, no. 4 (2007): 189–91.CrossRefGoogle Scholar
See FDA, supra note 2.Google Scholar
Id.Google Scholar
Ray, W. A. Stein, C. M., “Reform of Drug Regulation: Beyond an Independent Drug-Safety Board,” New England Journal of Medicine 354, no. 2 (2006): 194–201.CrossRefGoogle Scholar
Baluch, A. S., “Angstrom Medica: Securing FDA Approval and Commercializing a Nanomedical Device,” Nanotechnology Law and Business 2 (2005): 168–73.Google Scholar
Till, M. C. Simkin, M. M. Maebius, S., “Nanotech Meets the FDA: A Success Story about the First Nanoparticlate Drugs Approved by the FDA,” Nanotechnology Law and Business 2 (2005): 163–67.Google Scholar
See Faunce, , supra note 36.Google Scholar
The United Nations Conference on Environment and Development, Rio Declaration on Environment and Development, United Nations Environment Programme, 1992.Google Scholar
See The Royal Society, supra note 9.Google Scholar
Owens, J., “2006 Drug Approvals: Finding the Niche,” Nature Reviews Drug Discovery 6 (2007): 99–101.CrossRefGoogle Scholar
Vastg, B., “The Policy Outlook from the Hill,” Nature Biotechnology 25, no. 1 (2007): 13–16.CrossRefGoogle Scholar
See The Royal Society, supra note 9.Google Scholar
European Science Foundation, Nanomedicine: An ESF-European Medical Research Councils (EMRC) Forward Look Report, European Science Foundation, Strasbourg, 2005.Google Scholar
Moran, N., “Danish Biotech Outperforms its European Counterparts,” Nature Biotechnology 24 (2006): 1460–61.CrossRefGoogle Scholar
Australian Academy of Science, Nanotechnology Benchmarking Project, available at <http://www.science.org.au/policy/nano-exec.htm> (last visited September 14, 2007).+(last+visited+September+14,+2007).>Google Scholar
Australian Government, “Australian Nanotechnology: Capability and Commercial Potential,” 2nd ed., Canberra, 2005.Google Scholar
See Hulstein, et al. , supra note 16.Google Scholar
Institute for Soldier Nanotechnologies, Enhancing Soldier Survivability, MIT Web site, available at <http://web.mit.edu/ISN/> (last visited June 1, 2007).+(last+visited+June+1,+2007).>Google Scholar
Roco, M. C., “National Nanotechnology Investment in the FY 2003 Budget Request by the President,” National Nanotechnology Web site, available at <http://www.nano.gov/2003budget.html> (last visited September 14, 2007).+(last+visited+September+14,+2007).>Google Scholar
Reynolds, J. G. Hart, B. R., “Nanomaterials and Their Application to Defense and Homeland Security,” JOM 56, no. 1 (2004): 36–39.CrossRefGoogle Scholar
Faunce, T. A. Lexchin, J., “‘Linkage’ Pharmaceutical Evergreening in Canada and Australia,” Australian and New Zealand Journal of Health Policy 4, no. 1 (2007): 8 (online publication); Faunce, T. A., “Reference Pricing for Pharmaceuticals: Is the Australia-United States Free Trade Agreement Affecting Australia's Pharmaceutical Benefits Scheme?” Medical Journal of Australia 187, no. 4 (2007): 1–3.CrossRefGoogle Scholar
Lopez-Casasnovas, G. Puig-Junoy, J., “Review of the Literature on Reference Pricing” in Lopez-Casasnovas, G. Jonsson, B., eds., Reference Pricing and Pharmaceutical Policy (Barcelona: Springer-Verlag, 2001): At 13; Productivity Commission, International Pharmaceutical Price Differences: Research Report, Ausinfo, Canberra, 2001; Commonwealth of Australia, National Medicines Policy, Australian Government Web site, available at <http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-objectives-policy.htm> (last visited September 14, 2007); Office of the U.S. Trade Representative, Korea-United States Free Trade Agreement, at Chapter Five: Pharmaceutical and Medical Devices, available at <http://www.ustr.gov/Trade_Agreements/Bilateral/Republic_of_Korea_FTA/Draft_Text/Section_Index.html> (last visited September 14, 2007); von Weizsäcker, E. U. Young, O. R. Finger, M., eds., Limits to Privatisation: How to Avoid Too Much of a Good Thing? (London: Earthscan Publications, 2006).Google Scholar
Id. (Lopez-Cassanovas and Puig-Junoy).Google Scholar
Judgment No. T-505, August 28, 1992, Columbian Constitutional Court in (1992) 21 Revista Mensual Jurisprudencia Doctrina 1101, Amparo Action against the Ministry of Health, Supreme Court of Justice, Republic of Venezuela, June 9, 1998.Google Scholar
See Faunce, , supra note 28.Google Scholar
See generally Kahneman, D., “Maps of Bounded Rationality: Psychology for Behavioral Economics,” American Economic Review 93 (2003): 1449–75.CrossRefGoogle Scholar
Faunce, T. A., “Toward a Treaty on Safety and Cost-Effectiveness of Pharmaceuticals and Medical Devices: Enhancing an Endangered Global Public Good,” Globalization and Health 2 (2006): 5–15.CrossRefGoogle Scholar
Thomas, J., “Nanotechnology and Surveillance: Little Brother Is Watching You,” Chain Reaction 97 (2006): 29–33.Google Scholar
Monahan, T., ed., Surveillance and Security: Technological Politics and Power in Everyday Life (London: Routledge, 2006).CrossRefGoogle Scholar
United Nations, States Parties to Biological Weapons Convention Conclude Meeting After Discussing Scientific Codes of Conduct, Press Release DC05044E, New York, December 9, 2005.Google Scholar
Atlas, R., “Statement on Scientific Publication and Security,” Science 299 (2003): 1149–52.Google Scholar
Kaul, I., “Financing Global Public Goods: Challenges,” in Weizsäcker, et al. , eds., supra note 57, at 311.Google Scholar
Beauchamp, T. L., “Principlism and its Alleged Competitors,” Kennedy Institute of Ethics Journal 5, no. 3 (1995): 181–92.CrossRefGoogle Scholar
Faunce, T. A., “Developing and Teaching the Virtue-Ethics Foundations of Healthcare Whistle Blowing,” Monash Bioethics Review 23, no. 4 (2004): 41–55.CrossRefGoogle Scholar
U.S. National Academy of Sciences, Biotechnology Research in an Age of Terrorism (Washington, D.C.: National Academies Press, 2004).Google Scholar